VANDA PHARMACEUTICALS INC. Debt Securities Available For Sale Excluding Accrued Interest Current
VANDA PHARMACEUTICALS INC. (VNDA) had Debt Securities Available For Sale Excluding Accrued Interest Current of $114.15 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest Current $114.15M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest Current $148.28M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest Current $179.00M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest Current $223.73M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest Current |
|---|---|
| 2026-06-30 | $114.15M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $148.28M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $179.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $223.73M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $244.57M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $229.11M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $272.33M 10-K · filed 2026-02-12 |
| 2024-09-30 | $275.76M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $284.72M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $268.98M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $252.44M 10-K · filed 2025-02-14 |
| 2023-09-30 | $306.67M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $339.32M 10-Q · filed 2023-07-28 |
| 2023-03-31 | $147.32M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $331.83M 10-K · filed 2024-02-08 |
| 2022-09-30 | $405.39M 10-Q · filed 2022-11-03 |
| 2021-12-31 | $380.74M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |